Officials at the U.S. Department of Health and Human Services will restrict Medicare coverage of a new Alzheimer’s treatment to clinical trials, rejecting activists who had demanded full access for early-onset dementia patients.

Thursday’s decision from the department’s Centers for Medicare & Medicaid Services (CMS), affirms an earlier Jan. 11 …
Source: The Washington Times